抗体と薬物の結合体の定量化と薬動学的分析のためのバイオ分析方法における最近の進歩
R M Naseer Khan1, Yi Zeng1, Abdul-Azeez A Lanihun1
1Clinical Pharmacology Laboratory, Clinical Center, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 5A03, Bethesda, Maryland, 20892, USA.
The AAPS journal
|September 4, 2025
まとめ
抗体-薬物結合体 (ADC) の正確な特徴づけは,新しいがん治療法の開発に不可欠です. このレビューでは,ADCの安全性と有効性を向上させるための先進的な生物分析方法と薬理学モデリングを強調しています.
科学分野:
- バイオ医薬品分析
- 薬理学と薬物の代謝
- 腫瘍治療薬
背景:
- 抗体-薬剤結合剤 (ADC) は,抗体特異性と細胞毒性のペイロードを組み合わせた複雑な治療薬です.
- ADCの構造的異質性と複雑さは,正確な特徴と定量化のための重要なバイオ分析的な課題を提示します.
- 安全で効果的なADCの開発には,堅固な分析方法と薬動学的モデリングが不可欠です.
研究 の 目的:
- ADCの特徴づけのためのバイオ分析方法論の最近の進歩をレビューする.
- ADCの開発のための重要な薬動学 (PK) モデリングのアプローチについて議論する.
- ADCの特徴づけを強化し,治療開発を促進するための洞察を提供すること.
主な方法:
- ADCの検出と定量化のためのリガンド結合測定法 (LBAs)
- 詳細なADCプロファイリングのための液体染色体-タンデム質量スペクトロメトリ (LC-MS/MS).
- ハイブリッドのLBA-LC-MS/MSプラットフォームは,結合と質量スペクトロメトリを統合しています.
- 集団PKモデル,生理学的に基礎づけられた薬理学 (PBPK) および定量的なシステム薬理学 (QSP) のモデルをメカニズム的な理解のために使用する.
主要な成果:
- 最近の進歩により,ADCの生物分析の精度と感度が向上しています.
- 先進的な PK モデル (PBPK,QSP) は,ペイロードの解離と DAR 変動性を含む ADC 配置の詳細な特徴付けを可能にします.
- 生物分析データとPKモデリングの統合は,体内でのADCの行動の理解を高めます.
結論:
- ADCの複雑さに対処するために,堅固な生物分析方法が不可欠です.
- 先進的なPKモデリングは,ADCの薬理動力学と動力学に関する重要な洞察を提供します.
- これらのアプローチを統合することで,より安全で効果的なADC治療法の開発が容易になります.
関連する概念動画
01:22Protein-Drug Binding: Determination Methods
302
Determining protein-drug binding can be achieved through indirect and direct methods, each providing valuable insights into the interaction between proteins and drugs.
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...
302
01:23Drug Concentrations: Measurements
576
Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma...
Plasma...
576
00:59Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
124
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
124
01:29Drug Distribution: Plasma Protein Binding
6.6K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
6.6K